Current update in the management of diabetic nephropathy

Peter Noel Van Buren, Robert Toto

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease in the United States. The progression of kidney disease in patients with diabetes can take many years, and interventions such as glycemic control, blood pressure control, and inhibition of the renin-angiotensin-aldosterone system have been shown to slow this progression. Despite the implementation of these strategies, the number of patients with diabetes that ultimately develop end-stage renal disease remains high. Recent investigation has focused on the optimization of renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy using combinations of drugs that target this pathway. Additional investigation has focused on the potential of novel therapies that either target various pathways upregulated by hyperglycemia or other targets believed to promote progression of diabetic nephropathy such as the endothelin system, inflammation and vitamin D receptors. This review article addresses some of the well-established principles regarding the progression and accepted management of diabetic nephropathy and includes current updates on the most recent clinical research trials exploring novel therapeutics in this field.

Original languageEnglish (US)
Pages (from-to)62-77
Number of pages16
JournalCurrent Diabetes Reviews
Volume9
Issue number1
StatePublished - 2013

Fingerprint

Diabetic Nephropathies
Renin-Angiotensin System
Chronic Kidney Failure
Calcitriol Receptors
Endothelins
Kidney Diseases
Drug Combinations
Hyperglycemia
Clinical Trials
Blood Pressure
Inflammation
Therapeutics
Research

Keywords

  • Albuminuria
  • Diabetes
  • Diabetic nephropathy
  • Endothelin-1
  • Hypertension
  • Renin-angiotensin-aldosterone system

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Current update in the management of diabetic nephropathy. / Van Buren, Peter Noel; Toto, Robert.

In: Current Diabetes Reviews, Vol. 9, No. 1, 2013, p. 62-77.

Research output: Contribution to journalArticle

Van Buren, Peter Noel ; Toto, Robert. / Current update in the management of diabetic nephropathy. In: Current Diabetes Reviews. 2013 ; Vol. 9, No. 1. pp. 62-77.
@article{e44eb0451ec74fe190514a54c66c056a,
title = "Current update in the management of diabetic nephropathy",
abstract = "Diabetic nephropathy is the leading cause of end-stage renal disease in the United States. The progression of kidney disease in patients with diabetes can take many years, and interventions such as glycemic control, blood pressure control, and inhibition of the renin-angiotensin-aldosterone system have been shown to slow this progression. Despite the implementation of these strategies, the number of patients with diabetes that ultimately develop end-stage renal disease remains high. Recent investigation has focused on the optimization of renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy using combinations of drugs that target this pathway. Additional investigation has focused on the potential of novel therapies that either target various pathways upregulated by hyperglycemia or other targets believed to promote progression of diabetic nephropathy such as the endothelin system, inflammation and vitamin D receptors. This review article addresses some of the well-established principles regarding the progression and accepted management of diabetic nephropathy and includes current updates on the most recent clinical research trials exploring novel therapeutics in this field.",
keywords = "Albuminuria, Diabetes, Diabetic nephropathy, Endothelin-1, Hypertension, Renin-angiotensin-aldosterone system",
author = "{Van Buren}, {Peter Noel} and Robert Toto",
year = "2013",
language = "English (US)",
volume = "9",
pages = "62--77",
journal = "Current Diabetes Reviews",
issn = "1573-3998",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Current update in the management of diabetic nephropathy

AU - Van Buren, Peter Noel

AU - Toto, Robert

PY - 2013

Y1 - 2013

N2 - Diabetic nephropathy is the leading cause of end-stage renal disease in the United States. The progression of kidney disease in patients with diabetes can take many years, and interventions such as glycemic control, blood pressure control, and inhibition of the renin-angiotensin-aldosterone system have been shown to slow this progression. Despite the implementation of these strategies, the number of patients with diabetes that ultimately develop end-stage renal disease remains high. Recent investigation has focused on the optimization of renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy using combinations of drugs that target this pathway. Additional investigation has focused on the potential of novel therapies that either target various pathways upregulated by hyperglycemia or other targets believed to promote progression of diabetic nephropathy such as the endothelin system, inflammation and vitamin D receptors. This review article addresses some of the well-established principles regarding the progression and accepted management of diabetic nephropathy and includes current updates on the most recent clinical research trials exploring novel therapeutics in this field.

AB - Diabetic nephropathy is the leading cause of end-stage renal disease in the United States. The progression of kidney disease in patients with diabetes can take many years, and interventions such as glycemic control, blood pressure control, and inhibition of the renin-angiotensin-aldosterone system have been shown to slow this progression. Despite the implementation of these strategies, the number of patients with diabetes that ultimately develop end-stage renal disease remains high. Recent investigation has focused on the optimization of renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy using combinations of drugs that target this pathway. Additional investigation has focused on the potential of novel therapies that either target various pathways upregulated by hyperglycemia or other targets believed to promote progression of diabetic nephropathy such as the endothelin system, inflammation and vitamin D receptors. This review article addresses some of the well-established principles regarding the progression and accepted management of diabetic nephropathy and includes current updates on the most recent clinical research trials exploring novel therapeutics in this field.

KW - Albuminuria

KW - Diabetes

KW - Diabetic nephropathy

KW - Endothelin-1

KW - Hypertension

KW - Renin-angiotensin-aldosterone system

UR - http://www.scopus.com/inward/record.url?scp=84875962833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875962833&partnerID=8YFLogxK

M3 - Article

C2 - 23167665

AN - SCOPUS:84875962833

VL - 9

SP - 62

EP - 77

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

SN - 1573-3998

IS - 1

ER -